Literature DB >> 21071579

MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Yi Chen1, Mohd Saif Zaman, Guoren Deng, Shahana Majid, Shranjot Saini, Jan Liu, Yuichiro Tanaka, Rajvir Dahiya.   

Abstract

ARHI is an imprinted tumor suppressor gene and is downregulated in various malignancies. However, ARHI expression, function, and mechanisms of action in prostate cancer have not been reported. Here, we report that ARHI mRNA and protein levels were downregulated in prostate cancer tissues compared with adjacent normal tissues. Overexpression of ARHI inhibited cell proliferation, colony formation, invasion, and induced apoptosis. Further studies on a new mechanism of ARHI downregulation showed a significant inverse relationship between ARHI and miR-221 and 222, which were upregulated in prostate cancer cell lines. Transfection of miR-221 and 222 inhibitors into PC-3 cells caused a significant induction of ARHI expression. A direct interaction of miR-221 or 222 with a target site on the 3'UTR of ARHI was confirmed by a dual luciferase pMIR-REPORT assay. Finally, we also found that genistein upregulates ARHI by downregulating miR-221 and 222 in PC-3 cells. In conclusion, ARHI is a tumor suppressor gene downregulated in prostate cancer, and overexpression of ARHI can inhibit cell proliferation, colony formation, and invasion. This study demonstrates for the first time that prostate cancer cells have decreased level of ARHI which could be caused by direct targeting of 3'UTR of ARHI by miR221/222. Genistein, a potential nontoxic chemopreventive agent, restores expression of ARHI and may be an important dietary therapeutic agent for treating prostate cancer. ©2010 AACR

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071579      PMCID: PMC3894108          DOI: 10.1158/1940-6207.CAPR-10-0167

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  29 in total

1.  Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.

Authors:  Satoshi Fujii; Robert Z Luo; Jiuhong Yuan; Mitsutaka Kadota; Mitsuo Oshimura; Sharon R Dent; Yutaka Kondo; Jean-Pierre J Issa; Robert C Bast; Yinhua Yu
Journal:  Hum Mol Genet       Date:  2003-08-01       Impact factor: 6.150

2.  Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.

Authors:  Hideki Ouchi; Hitoshi Ishiguro; Naoya Ikeda; Mayumi Hori; Yoshinobu Kubota; Hiroji Uemura
Journal:  Int J Urol       Date:  2005-01       Impact factor: 3.369

3.  Synergistic effects of thearubigin and genistein on human prostate tumor cell (PC-3) growth via cell cycle arrest.

Authors:  K Sakamoto
Journal:  Cancer Lett       Date:  2000-04-03       Impact factor: 8.679

4.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

5.  Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.

Authors:  Lin Wang; Ashraful Hoque; Robert Z Luo; Jiuhong Yuan; Zhen Lu; Arata Nishimoto; Jinsong Liu; Aysegul A Sahin; Scott M Lippman; Robert C Bast; Yinhua Yu
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

6.  Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.

Authors:  Daniel G Rosen; Lin Wang; Ajay N Jain; Karen H Lu; Robert Z Luo; Yinhua Yu; Jinsong Liu; Robert C Bast
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

7.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Authors:  Y Yu; F Xu; H Peng; X Fang; S Zhao; Y Li; B Cuevas; W L Kuo; J W Gray; M Siciliano; G B Mills; R C Bast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

8.  Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.

Authors:  Jia-Ju Bao; Xiao-Feng Le; Rui-Yu Wang; Jiuhong Yuan; Lin Wang; Edward N Atkinson; Ruth LaPushin; Michael Andreeff; Bingliang Fang; Yinhua Yu; Robert C Bast
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

9.  ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis.

Authors:  Jian Huang; Yun Lin; Lihua Li; Deng Qing; Xiao-Mei Teng; Yun-Li Zhang; Xin Hu; Yuanjie Hu; Pengyuan Yang; Ze-guang Han
Journal:  Mol Carcinog       Date:  2009-02       Impact factor: 4.784

10.  Genistein chemoprevention of prostate cancer in TRAMP mice.

Authors:  Jun Wang; Isam-Eldin Eltoum; Coral A Lamartiniere
Journal:  J Carcinog       Date:  2007-03-16
View more
  65 in total

Review 1.  MicroRNA, nutrition, and cancer prevention.

Authors:  Sharon A Ross; Cindy D Davis
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

Review 2.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

3.  ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.

Authors:  Z Lu; H Yang; M N Sutton; M Yang; C H Clarke; W S-L Liao; R C Bast
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

4.  DNA Methylation and Flavonoids in Genitourinary Cancers.

Authors:  Neelam Mukherjee; Addanki P Kumar; Rita Ghosh
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

5.  Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis [corrected].

Authors:  Chiranjib Chakraborty; C George Priya Doss; Renu Sarin; Minna J Hsu; Govindasamy Agoramoorthy
Journal:  Protoplasma       Date:  2015-02-20       Impact factor: 3.356

Review 6.  Epigenetic linkage of aging, cancer and nutrition.

Authors:  Michael Daniel; Trygve O Tollefsbol
Journal:  J Exp Biol       Date:  2015-01-01       Impact factor: 3.312

7.  Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.

Authors:  Ying Li; Mei Liu; Yanjun Zhang; Chun Han; Junhao You; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2013-06-26

Review 8.  MicroRNA and cancer chemoprevention.

Authors:  Bin Yi; Gary A Piazza; Xiulan Su; Yaguang Xi
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26

Review 9.  miR-221/222: promising biomarkers for breast cancer.

Authors:  Wei-Xian Chen; Qing Hu; Man-Tang Qiu; Shan-Liang Zhong; Jin-Jin Xu; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Tumour Biol       Date:  2013-03-27

10.  MicroRNAs: New players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways.

Authors:  Chengyue Zhang; Limin Shu; Ah-Ng Tony Kong
Journal:  Curr Pharmacol Rep       Date:  2015-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.